Navigation Links
Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement

IRVINE, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has filed a motion to stay, or discontinue all proceedings in, the patent infringement lawsuit brought against it in October 2009 by Cook, Inc. The motion was filed in the United States District Court in Indianapolis, Indiana.

Endologix has requested that the stay remain in effect while the United States Patent and Trademark Office (USPTO) conducts proceedings to re-examine the two patents asserted by Cook in the lawsuit and determine whether it should have granted Cook the patents. Endologix has already filed papers requesting that the USPTO re-examine the two Cook patents, based on patents that pre-date Cook's patents and were not previously considered by the USPTO in its decision to grant the patents to Cook.

John McDermott, Endologix President and Chief Executive Officer, said, "In addition to contesting the validity of Cook's patents, we also intend to challenge the lawsuit on other grounds, including non-infringement of the Cook patents by our products. We continue to believe we have support for numerous promising defenses against this infringement case."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the claims of alleged infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

Endologix, Inc.                      The Ruth Group
John McDermott, CEO                  Nick Laudico (646) 536-7030
(949) 595-7200                       Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
10. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
11. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical ... is pleased to announce the appointment of Anders ... Dr. Jonzon ... cardiology at Children,s Hospital, Uppsala University, Uppsala and Children,s ... 1984-1986, he was a fellow at the Cardiovascular Institute ...
(Date:11/24/2015)... and BERN, Switzerland , November ... ARTORG Center for Biomedical Engineering Research of the University ... Division of Endocrinology, Diabetes and Clinical Nutrition of the ... start of an exclusive collaboration to develop a novel ... for the personalised delivery of insulin for diabetic patients ...
(Date:11/24/2015)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that ... and Human Resources will be presenting in the upcoming Atlantic ... Strategies for a Dynamic Market" on Dec. 1, 2015. Rice ... with the Cambridge Advisory Group, where she leads their pharmacy ... webinar will discuss the rapid growth of oral oncolytics, the ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA ... EST, , FDA has long asserted that design and manufacture of ... the tests and do not meet the device regulations. , Come up short in ...
(Date:11/24/2015)... Indianapolis, IN (PRWEB) , ... November 24, 2015 ... ... employee benefits advisory organization, is pleased to welcome Winter-Dent & Company as its ... strive from day one to become a client's most trusted advisor regardless of ...
(Date:11/24/2015)... , ... November 24, 2015 , ... With Thanksgiving right ... is sharing safety tips to help protect your family and vehicle. , According to ... the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from the ...
(Date:11/24/2015)... ... 2015 , ... Dr. Rodney E. Willey , has answered a new calling – to ... Disorders, provides treatment for snoring and sleep apnea through oral appliance therapy. ... Sleep Disorders in the US, one of four in the Illinois area. , Dr. ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... Dr. ... his office to help the community stress less this holiday season. During the ... additional stress in people's lives and the team at AlignLife want to help provide ...
Breaking Medicine News(10 mins):